Last updated on October 2017

Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ulcerative Colitis
  • Age: Between 18 - 80 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Moderately to severely active UC as determined by the Mayo Clinic Score assessment (MCS)
  2. Intolerance, loss response or failure to respond to treatment with at least one TNF-inhibitor within the previous 5 years
  3. Washout of anti-TNF therapy for at least 8 weeks preceding Day 1
  4. Background regimen for UC may include oral 5-aminosalicylic acid (5-ASA), oral corticosteroids, budesonide multi-matrix system (MMX), probiotics, azathioprine (AZA), 6-mercaptopurine (6-MP), or methotrexate (MTX) if doses have been stable during the screening period
  5. Use of highly effective contraception as defined by the protocol
  6. Must have received a colonoscopy within the past year or be willing to undergo a colonoscopy in lieu of a flexible sigmoidoscopy at screening.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.